BI
CRVS icon

BVF Inc’s Corvus Pharmaceuticals CRVS Stock Holding History

BVF Inc’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-361,406
Closed -$643K – 62
2024
Q1 		$643K Sell
361,406
-1,009,541
-74% -$2.11M 0.02% 61
2023
Q4 		$2.41M Hold
1,370,947
– – 0.06% 62
2023
Q3 		$2M Hold
1,370,947
– – 0.05% 62
2023
Q2 		$3.14M Hold
1,370,947
– – 0.09% 59
2023
Q1 		$1.25M Hold
1,370,947
– – 0.05% 67
2022
Q4 		$1.17M Hold
1,370,947
– – 0.05% 72
2022
Q3 		$1.12M Hold
1,370,947
– – 0.05% 73
2022
Q2 		$1.36M Hold
1,370,947
– – 0.07% 72
2022
Q1 		$2.25M Hold
1,370,947
– – 0.09% 74
2021
Q4 		$3.3M Hold
1,370,947
– – 0.12% 71
2021
Q3 		$6.63M Sell
1,370,947
-2,307,679
-63% -$6.83M 0.26% 63
2021
Q2 		$9.82M Buy
3,678,626
+449,200
+14% +$1.24M 0.37% 50
2021
Q1 		$9.95M Buy
3,229,426
+1,285,714
+66% +$4.64M 0.37% 50
2020
Q4 		$6.92M Buy
1,943,712
+200,000
+11% +$805K 0.27% 50
2020
Q3 		$6.99M Buy
1,743,712
+1,600
+0.1% +$6.39K 0.38% 49
2020
Q2 		$4.74M Sell
1,742,112
-414,628
-19% -$1.23M 0.29% 48
2020
Q1 		$4.55M Buy
2,156,740
+529,172
+33% +$2.15M 0.42% 42
2019
Q4 		$8.85M Sell
1,627,568
-1,419,587
-47% -$4.97M 0.67% 33
2019
Q3 		$9.17M Buy
3,047,155
+272,405
+10% +$1.14M 0.96% 30
2019
Q2 		$10.4M Buy
2,774,750
+665,408
+32% +$2.61M 1.13% 28
2019
Q1 		$8.48M Buy
2,109,342
+218,835
+12% +$924K 0.95% 34
2018
Q4 		$6.94M Hold
1,890,507
– – 0.91% 32
2018
Q3 		$16.2M Hold
1,890,507
– – 1.43% 22
2018
Q2 		$20.8M Sell
1,890,507
-63,747
-3% -$712K 2.03% 20
2018
Q1 		$22.5M Buy
1,954,254
+1,494,858
+325% +$14.1M 2.28% 17
2017
Q4 		$4.76M Hold
459,396
– – 0.57% 34
2017
Q3 		$7.32M Buy
459,396
+185,200
+68% +$2.56M 0.93% 29
2017
Q2 		$3.32M Buy
+274,196
New +$2.93M 0.52% 29

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TL
TowerView LLC New York $155M AUM 30.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BVF Inc's CRVS Position: Q2 2024 in Review

BVF Inc sold out of Corvus Pharmaceuticals (CRVS) in Q2 2024, closing a stake of 361,406 shares — an estimated $643K sold.

BVF Inc first reported a position in CRVS in Q2 2017 and held it in 28 quarters. The position peaked at $22.5M in Q1 2018. 47 funds tracked by Wall St. Rank hold CRVS as of Q2 2024.

  • BVF Inc reported no remaining Corvus Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • BVF Inc sold 361,406 Corvus Pharmaceuticals shares in Q2 2024, an estimated $643K.
  • BVF Inc first reported a position in Corvus Pharmaceuticals in Q2 2017 and held it in 28 quarters.
  • BVF Inc's Corvus Pharmaceuticals position peaked at $22.5M in Q1 2018.
  • 47 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2024.

Based on BVF Inc's 13F filing for Q2 2024, filed 14 Aug 2024.